Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Selectively Targeting Checkpoint Kinase By Prexasertib Had Potent Anti-Tumor Activity As Single Agent or Combined with Other Chemotherapeutic Drugs in Diffuse Large B-Cell Lymphoma, Especially Double Hit Lymphoma

Juan Gu, MD PhD, Dennis C Gaughan, Simran Gill, Cory Mavis, BSc, MSc, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2018) 132 (Supplement 1): 5151.

https://doi.org/10.1182/blood-2018-99-110282

Published: 2018

Journal Articles

Synthetic Lethal Screening Identifies CHK1 Inhibition As an Exploitable Vulnerability in EZH2 Deficient T-ALL

Theresa E. Leon, PhD MSc, BSc, Tanya Rapoz-D'Silva, BSc, MSc, Sunniyat Rahman, MBiochem, DIC, PhD, Michael Magnussen, BSc, MSc, Nadine Farah, MBBChir, MA, MRCP, FRCPath, Jose A. Guerra-Assunção, BSc, PhD, Rajeev Gupta, MB.ChB, PhD FRCP, FRCPath, Elisabeth P. Nacheva, MD PhD, Javier Herrero, PhD, David C. Linch, FRCP, Marc R. Mansour, MD PhD FRCPath

Blood (2017) 130 (Supplement 1): 1325.

https://doi.org/10.1182/blood.V130.Suppl_1.1325.1325

Published: 2017

Journal Articles

The Cytotoxic Effect of the PARP Inhibitor ABT-888 on Myeloproliferative Neoplasms

Pritesh R. Patel, MB, ChB, Vitalyi Senyuk, PhD, Elisa Bonetti, PhD, Dolores Mahmud, PhD, Shrihari S. Kadkol, MD PhD, Annie L. Oh, MD, Nadim Mahmud, MD PhD, Damiano Rondelli, MD

Blood (2016) 128 (22): 4276.

https://doi.org/10.1182/blood.V128.22.4276.4276

Published: 2016

Journal Articles

ANKHD1 Silencing Delays S Phase Progression in Multiple Myeloma Cells Via Activation of ATM/ATR -CDC25a Pathway

Dhyani Anamika, Patricia Favaro, PhD, Sara Teresinha Olalla Saad, MD PhD

Blood (2016) 128 (22): 5624.

https://doi.org/10.1182/blood.V128.22.5624.5624

Published: 2016

Journal Articles

Inhibition of WEE1 Induces Cell Death of Both Bortezomib- and Lenalidomide-Resistant Multiple Myeloma Cells: A Novel Therapeutic Approach Targeting Cell-Cycle Checkpoint Kinase

Takayuki Tabayashi, MD PhD, Yuka Tanaka, MD, Yasuyuki Takahashi, MD, Yuta Kimura, MD, Tatsuki Tomikawa, MD, Morihiko Sagawa, MD PhD, Tomoe Anan-Nemoto, MDPhD, Reiko Watanabe, MD PhD, Michihide Tokuhira, MD PhD, Masahiro Kizaki, MD PhD

Blood (2016) 128 (22): 3256.

https://doi.org/10.1182/blood.V128.22.3256.3256

Published: 2016

Journal Articles

Inhibition of CHK1 Enhances Cell Death Induced By the Bcl-2-Selective Inhibitor ABT-199 in Acute Myeloid Leukemia Cells

Jianyun Zhao, Xiaojia Niu, Holly Edwards, Yue Wang, Jeffrey W Taub, MD, Hai Lin, Yubin Ge, PhD

Blood (2015) 126 (23): 2469.

https://doi.org/10.1182/blood.V126.23.2469.2469

Published: 2015

Journal Articles

The Inhibition of Checkpoint Kinase 1 As a Promising Strategy to Increase the Effectiveness of Different Treatments in Acute Lymphoblastic Leukemia

Andrea Ghelli Luserna Di Rora, Ilaria Iacobucci, PhD, Enrica Imbrogno, Enrico Derenzini, MD, Anna Ferrari, PhD, Viviana Guadagnuolo, PhD, Valentina Robustelli, Simona Soverini, Cristina Papayannidis, MD PhD, Maria Chiara Abbenante, MD, Michele Cavo, MD, Giovanni Martinelli, MD PhD

Blood (2015) 126 (23): 2478.

https://doi.org/10.1182/blood.V126.23.2478.2478

Published: 2015

Journal Articles

Randomized Phase II Trial of Timed Sequential Cytosine Arabinoside with and without the CHK1 Inhibitor MK-8876 in Adults with Relapsed and Refractory Acute Myelogenous Leukemia

Jonathan Allen Webster, MD, Raoul Tibes, MD PhD, Amanda Blackford, ScM, Lawrence Morris, MD, Mrinal M Patnaik, MBBS, Lihua Wang, PhD, Melanie Rebechi, BS, Jacqueline Greer, RN, Mark R Litzow, MD, Larry Karnitz, PhD, Gary L. Rosner, Austin Doyle, MD, Scott H. Kaufmann, MD PhD, Judith E Karp, MD, B. Douglas Smith, MD

Blood (2015) 126 (23): 2563.

https://doi.org/10.1182/blood.V126.23.2563.2563

Published: 2015

Journal Articles

The Biologic Relevance of PIM Kinases in the Context of Multiple Myeloma and Their Potential As Therapeutic Targets in Combination Drug Therapy

Janani Ramachandran, MA, Loredana Santo, MD, Homare Eda, MDPhD, Dharminder Chauhan, PhD, Ka Tat Siu, PhD, Miroslav Koulnis, PhD, Dennis Huszar, PhD, Kenneth C Anderson, MD, Noopur S. Raje, MD

Blood (2015) 126 (23): 2992.

https://doi.org/10.1182/blood.V126.23.2992.2992

Published: 2015

Journal Articles

Effect of the Pan-PIM Kinase Inhibitor, AZD1208, Alone and in Combination with Bortezomib in Multiple Myeloma

Loredana Santo, Janani Ramachandran, Diana D Cirstea, Homare Eda, Neeharika Nemani, Teru Hideshima, Chauhan Dharminder, Dennis Huszar, PhD, Kenneth C. Anderson, MD, Noopur Raje, MD

Blood (2014) 124 (21): 5726.

https://doi.org/10.1182/blood.V124.21.5726.5726

Published: 2014

Journal Articles

Identification of Novel Therapeutic Strategies for NUP98-NSD1-Positive AML By Drug Sensitivity Profiling

Jarno Kivioja, MSc, Mika Kontro, MD, Angeliki Thanasopoulou, PhD, Muntasir Mamun Majumder, MSc,BPharm, Bhagwan Yadav, MSc, Heikki Kuusanmäki, MSc, Alun Parsons, MSc, Juerg Schwaller, MD, Kimmo Porkka, MD PhD, Caroline A Heckman, PhD

Blood (2014) 124 (21): 2160.

https://doi.org/10.1182/blood.V124.21.2160.2160

Published: 2014

Journal Articles

In Vitro and in Vivo Single-Agent Efficacy of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) Inhibitor PF-0477736 (Pfizer) in B- and T-Acute Lymphoblastic Leukemia (ALL)

Ilaria Iacobucci, Andrea Ghelli Luserna Di Rorà, Maria Vittoria Verga Falzacappa, Enrico Derenzini, MD, Anna Ferrari, Cristina Papayannidis, Claudia Venturi, Annalisa Lonetti, Viviana Guadagnuolo, Federica Cattina, Emanuela Ottaviani, Maria Chiara Abbenante, Domenico Russo, Michele Baccarani, MD, Pier Giuseppe Pelicci, Giovanni Martinelli, MD

Blood (2012) 120 (21): 1496.

https://doi.org/10.1182/blood.V120.21.1496.1496

Published: 2012

Journal Articles

Inhibition of Chk1 Kinase Sensitizes Leukemia and Lymphoma Cell Lines with TP53 M utations to Chemotherapy.

Jana Zemanova, Ludmila Sebejova, Dr., Ondrej Hylse, Kamil Paruch, Ph.D., Sarka Pavlova, Jiri Mayer, M.D., PhD., Prof., Sarka Pospisilova, Dr., PhD, Prof., Martin Trbusek, Dr., PhD.

Blood (2012) 120 (21): 2460.

https://doi.org/10.1182/blood.V120.21.2460.2460

Published: 2012

Journal Articles

The Novel Small Molecule Chk1/Chk2 Inhibitor PF-0477736 (Pfizer) Is Highly Active As Single Agent in Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Blood (2011) 118 (21): 76.

https://doi.org/10.1182/blood.V118.21.76.76

Published: 2011

Journal Articles

Disruption of Src function potentiates Chk1-inhibitor–induced apoptosis in human multiple myeloma cells in vitro and in vivo

Yun Dai, Shuang Chen, Rena Shah, Xin-Yan Pei, Li Wang, Jorge A. Almenara, Lora B. Kramer, Paul Dent, Steven Grant

Blood (2011) 117 (6): 1947–1957.

https://doi.org/10.1182/blood-2010-06-291146

Published: 2011

Includes: Supplemental data

Journal Articles

Constitutive Cyclin A1 Expression Impairs Retinoic Acid-Induced Growth Arrest and Differentiation of Myeloid Leukemia Cells

Tsuyoshi Nakamaki, MD, Kunihiko Fukuchi, Takashi Maeda, Norimichi Hattori, Hirotsugu Ariizumi, Bungo Saito, MD, Takaji Yanagisawa, Isao Matsuda, Shigeru Tomoyasu

Blood (2010) 116 (21): 2894.

https://doi.org/10.1182/blood.V116.21.2894.2894

Published: 2010

Journal Articles

Constitutive Cyclin A1 Expression Induces Abrogation of Cell Cycle Check Points Associated with Ara-C Resistance in Myeloid Leukemia Cells.

Tsuyoshi Nakamaki, Kunihiko Fukuchi, Norimichi Hattori, Hidetoshi Nakashima, Takashi Maeda, Kouji Yanagisawa, Bungo Saito, Isao Matsuda, Shigeru Tomoyasu

Blood (2009) 114 (22): 4801.

https://doi.org/10.1182/blood.V114.22.4801.4801

Published: 2009

Journal Articles

Chk1 Haploinsufficiency Results in Anemia and Defective Erythropoiesis

Nathan C Boles, Sirisha Peddibhotla, Alice Chen, Jeffrey Rosen, Margaret A. Goodell, PhD

Blood (2008) 112 (11): 3457.

https://doi.org/10.1182/blood.V112.11.3457.3457

Published: 2008

Journal Articles

ATR-Chk1 Axis Is Activated, but the Function of Chk1 Is Disrupted in BCR/ABL Leukemia Cells Responding to DNA Damage.

Margaret Nieborowska, MD, PhD, Tomasz Stoklosa, MD, PhD, Mandrita Datta, Agnieszka Czechowska, Lori Rink, Janusz Blasiak, PhD, Tomasz Skorski, MD, PhD

Blood (2005) 106 (11): 2883.

https://doi.org/10.1182/blood.V106.11.2883.2883

Published: 2005

Journal Articles

Differential Phosphorylation of FANCA and FANCG Determines Response of Fanconi Anemia Core Complex to DNA Damage and S Phase.

Jun Mi, Ph.D., Andrei Tomashevski, Ph.D., Gary M. Kupfer, M.D.

Blood (2004) 104 (11): 726.

https://doi.org/10.1182/blood.V104.11.726.726

Published: 2004

NARROW

Selectively Targeting Checkpoint Kinase By Prexasertib Had Potent Anti-Tumor Activity As Single Agent or Combined with Other Chemotherapeutic Drugs in Diffuse Large B-Cell Lymphoma, Especially Double Hit Lymphoma

Synthetic Lethal Screening Identifies CHK1 Inhibition As an Exploitable Vulnerability in EZH2 Deficient T-ALL

The Cytotoxic Effect of the PARP Inhibitor ABT-888 on Myeloproliferative Neoplasms

ANKHD1 Silencing Delays S Phase Progression in Multiple Myeloma Cells Via Activation of ATM/ATR -CDC25a Pathway

Inhibition of WEE1 Induces Cell Death of Both Bortezomib- and Lenalidomide-Resistant Multiple Myeloma Cells: A Novel Therapeutic Approach Targeting Cell-Cycle Checkpoint Kinase

Inhibition of CHK1 Enhances Cell Death Induced By the Bcl-2-Selective Inhibitor ABT-199 in Acute Myeloid Leukemia Cells

The Inhibition of Checkpoint Kinase 1 As a Promising Strategy to Increase the Effectiveness of Different Treatments in Acute Lymphoblastic Leukemia

Randomized Phase II Trial of Timed Sequential Cytosine Arabinoside with and without the CHK1 Inhibitor MK-8876 in Adults with Relapsed and Refractory Acute Myelogenous Leukemia

The Biologic Relevance of PIM Kinases in the Context of Multiple Myeloma and Their Potential As Therapeutic Targets in Combination Drug Therapy

Effect of the Pan-PIM Kinase Inhibitor, AZD1208, Alone and in Combination with Bortezomib in Multiple Myeloma

Identification of Novel Therapeutic Strategies for NUP98-NSD1-Positive AML By Drug Sensitivity Profiling

In Vitro and in Vivo Single-Agent Efficacy of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) Inhibitor PF-0477736 (Pfizer) in B- and T-Acute Lymphoblastic Leukemia (ALL)

Inhibition of Chk1 Kinase Sensitizes Leukemia and Lymphoma Cell Lines with TP53 M utations to Chemotherapy.

The Novel Small Molecule Chk1/Chk2 Inhibitor PF-0477736 (Pfizer) Is Highly Active As Single Agent in Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Disruption of Src function potentiates Chk1-inhibitor–induced apoptosis in human multiple myeloma cells in vitro and in vivo

Constitutive Cyclin A1 Expression Impairs Retinoic Acid-Induced Growth Arrest and Differentiation of Myeloid Leukemia Cells

Constitutive Cyclin A1 Expression Induces Abrogation of Cell Cycle Check Points Associated with Ara-C Resistance in Myeloid Leukemia Cells.

Chk1 Haploinsufficiency Results in Anemia and Defective Erythropoiesis

ATR-Chk1 Axis Is Activated, but the Function of Chk1 Is Disrupted in BCR/ABL Leukemia Cells Responding to DNA Damage.

Differential Phosphorylation of FANCA and FANCG Determines Response of Fanconi Anemia Core Complex to DNA Damage and S Phase.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only